



MDS Foundation

The Myelodysplastic Syndromes Foundation, Inc.

Myelodysplastic Syndromes 2023: What's New

ASH 2023 – Friday Satellite Symposium

Dec 8, 2023, 7:00 am – 10:00 am PT

San Diego Marriott Marquis



MDS Foundation

The Myelodysplastic Syndromes Foundation, Inc.

Myelodysplastic Syndromes 2023: What's New ASH 2023 – Friday Satellite Symposium


MDS Challenges in 2023

Moshe Mittelman

Tel-Aviv, Israel

Myelodysplastic Syndromes (MDS): General


- **Clonal BM stem cell disease(s)**
- **Abnormal hematopoiesis:**
 - differentiation, maturation, apoptosis
- **Genetic** (Immune) basis
- **Anemia (95%); Cytopenias**
- Median age: 74 yr
- Incidence increases with age
- Patients are classified – LR / HR
- Leukemic transformation (20%-60%)



Malcovati L, Blood 2013;122:2943; Tefferi A, NEJM 2009; 361: 1872
Ades L, Lancet 2014;383:2293; Rollison DE, Blood 2008; 112: 45
deSwart L BJH 2015;170:372; Mittelman M Is J Med Sci 1990;26:468;
Greenberg P, Blood 1997; 2012

MDS 2023: Challenges - Diagnosis

- **Today:** Based on BM
- **Problems:**
 - **Not early** enough – missing Pre-MDS sites
 - Individuals at risk
 - **BM** examination:
 - Invasive (old)
 - Morphology – (semi) subjective
 - 15-25% inter-observer differences
- **Solutions - add:**
 - Genetics;
 - Digital tools
 - Others ?



© Mayo Foundation for Medical Education and Research. All rights reserved.



MDS 2023: Challenges Prognosis / Classification (s)

- MDS – heterogenous
- Predicting prognosis - mandatory
- Tool – **Classification (S)**
 - **FAB (1982)** *Bennett, BJH 1982*
 - **WHO (1999; 2008; 2016)** *Arber DA Blood 2016*
 - **IPSS / IPSS-R** *Greenberg Blood 1997; 2012*
 - **IPSS-M (2022)** *Bernard NEJM Evidence 2022*
 - **5th WHO classification** *Khoury Leukemia 2022*
 - **ICC: Intern. Consensus Classification** *Arber Blood 2022; Cazzola Blood 2022*
- Harmonization ?



MDS 2023: Challenges - Treatment (I)

- **Lower-Risk MDS:**
 - **Anemia**
 - RBC transfusions - still ?
 - ESAs – still 1st Line ?
 - Luspatercept – role ?
 - Lenalidomide – only for del (5q) ?
 - Novel agents ?
 - **Thrombocytopenia**
 - Still embargo ?
 - Novel agents ?



MDS 2023: Challenges - Treatment (II)

- **Higher-Risk MDS:**
 - Still HMA ?
 - Can we overcome the barrier ?
 - 50% response rate; 2-year response duration
 - Novel agents ?
 - In combination ?
 - Targeted therapy ?
 - Role of chemotherapy
 - Stem cell transplant
 - Novel Immune approach
 - CAR-T ?



MDS 2023: Challenges – Other

- **Biology/Pathogenesis**
 - Better understanding
 - Inflammaging
 - Role of microenvironment
- **Genetics**
 - Interaction; Co-mutations; Gene function
- **Iron chelation**
- **Quality of life**
- **Financial toxicity**
 - Access to medications
- **Guidelines**



CME Pre-Test

Please complete a
brief CME Pre-test for
today's symposium

